FAQ: Quantum BioPharma's CVR Distribution and Litigation Details
Summary
Quantum BioPharma has set October 27, 2025 as the record date for distributing contingent value rights (CVRs) to Class B shareholders, which entitle holders to a portion of potential litigation proceeds exceeding $700 million. This distribution represents a potential financial benefit tied to the outcome of the company's ongoing legal action against major financial institutions.
What is the main announcement from Quantum BioPharma?
Quantum BioPharma has established October 27, 2025 as the record date for distributing contingent value rights (CVRs) to holders of its Class B Subordinate Voting Shares on a one-for-one basis, which entitle shareholders to a portion of potential litigation proceeds.
What are the CVRs and what do they entitle holders to?
Each CVR entitles holders to a pro rata portion of between 10% and 50% of any net proceeds ultimately recovered from the company’s ongoing litigation against CIBC World Markets, RBC Dominion Securities, and others, which seeks damages exceeding USD $700 million.
When is the record date for the CVR distribution?
The record date for the CVR distribution is October 27, 2025, meaning shareholders who hold Class B Subordinate Voting Shares on this date will be eligible to receive the CVRs.
What are the key terms and restrictions of the CVRs?
The CVRs are non-transferable, carry no interest or voting rights, and will only be redeemable for cash if Qualifying Net Proceeds are received through settlement or a final, non-appealable judgment from the litigation.
What is Quantum BioPharma’s primary business focus?
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different stages of development.
What is Lucid-MS and how does it relate to Quantum BioPharma?
Lucid-MS is Quantum BioPharma’s lead compound developed through its wholly owned subsidiary Lucid Psycheceuticals Inc., which is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
What is Quantum BioPharma’s relationship with Unbuzzd Wellness Inc.?
Quantum BioPharma invented unbuzzd(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining 20.11% ownership and receiving royalty payments of 7% of sales until payments total $250 million, then 3% in perpetuity, while keeping 100% rights for pharmaceutical and medical uses.
Where can investors find more information about Quantum BioPharma?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://www.investorbrandnetwork.com/clients/quantum-biopharma-ltd/ and the full press release can be viewed at https://ibn.fm/P9Wrt
What other business activities does Quantum BioPharma engage in?
Through its wholly owned subsidiary FSD Strategic Investments Inc., Quantum BioPharma maintains a portfolio of strategic investments representing loans secured by residential or commercial property.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 242604